The definition of remission in asthma should be unique and specific.
作者信息
Yilmaz İnsu, Paçaci Çetin Gülden, Türk Murat
机构信息
Division of Immunology and Allergy, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye.
Clinic of Immunology and Allergy, Kocaeli City Hospital, Kocaeli, Türkiye.
出版信息
Tuberk Toraks. 2024 Jun;72(2):176-178. doi: 10.5578/tt.202402909.
Abstract
摘要
相似文献
1
The definition of remission in asthma should be unique and specific.哮喘缓解的定义应该是独特且明确的。
Tuberk Toraks. 2024 Jun;72(2):176-178. doi: 10.5578/tt.202402909.
2
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南（2024年版）]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
3
Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.倍利珠单抗推进重度哮喘缓解：最新发现、当前观点及未来方向
Clin Exp Allergy. 2025 Jul;55(7):521-531. doi: 10.1111/cea.70083. Epub 2025 May 30.
4
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts.开发哮喘医疗负担评分作为SARP III和U-BIOPRED中严重程度的衡量指标及缓解的预测指标：来自两个主要哮喘纵向队列的结果
Lancet Respir Med. 2025 Jan;13(1):35-46. doi: 10.1016/S2213-2600(24)00250-9. Epub 2024 Nov 22.
5
Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma.特泽佩umab实现临床和生物学缓解：重度难治性哮喘的真实世界反应
Allergy. 2025 Jun;80(6):1669-1676. doi: 10.1111/all.16590. Epub 2025 May 14.
6
Biologic treatment discontinuation in severe asthma: A real-life study on factors influencing clinical remission and physician decision-making.重度哮喘患者生物治疗的停药情况：一项关于影响临床缓解及医生决策因素的真实病例研究
Allergy Asthma Proc. 2025 Jul 1;46(4):287-295. doi: 10.2500/aap.2025.46.250023.
7
Response to IL-5/IL-5R Antagonists and Remission Rate in Patients With Severe Asthma Who Would Have Been Excluded From the Pivotal Clinical Trials.对白细胞介素-5/白细胞介素-5受体拮抗剂的反应以及在严重哮喘患者中的缓解率，这些患者原本会被排除在关键临床试验之外。
J Allergy Clin Immunol Pract. 2025 Jul;13(7):1768-1775. doi: 10.1016/j.jaip.2025.03.025. Epub 2025 Mar 26.
8
Exploring factors associated with clinical remission in patients with severe asthma receiving anti-IL-4Rα, anti-IL-5/5R, or anti-IgE treatment.
Respir Investig. 2025 Jul;63(4):633-638. doi: 10.1016/j.resinv.2025.05.005. Epub 2025 May 16.
9
Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options.哮喘儿童运动诱发的支气管收缩：现有治疗方案的比较性系统评价
Drugs. 2009 Aug 20;69(12):1533-53. doi: 10.2165/11316720-000000000-00000.
10
Treatable Traits as a Pathway to Remission in Asthma.可治疗特征作为哮喘缓解的途径。
J Allergy Clin Immunol Pract. 2025 Jul;13(7):1542-1552. doi: 10.1016/j.jaip.2025.05.002. Epub 2025 May 8.
Zotero 插件